RxDoctor Payments Data

Vicente Lago, MD

Gastroenterology · Miami, FLNPI 1619068095

Payments from drug & device makers

$9,512in general payments, 2019–2025

Across 529 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • QOL Medical, LLC$1K
  • Ironwood Pharmaceuticals, Inc$402
  • Madrigal Pharmaceuticals$368
  • Phathom Pharmaceuticals, Inc.$326
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$9,506100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,512 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$29,791
Medicare patients
109
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase43$98,211
LinzessLinaclotide99$78,529
CreonLipase/Protease/Amylase19$51,239
ViberziEluxadoline27$33,362
TrulancePlecanatide30$25,326
Mesalamine25$17,934
VoqueznaVonoprazan Fumarate15$10,957
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates106$6,272
ClenpiqSod Picosulf/Mag Ox/Citric Ac35$6,146
Dexlansoprazole DrDexlansoprazole19$5,583
Famotidine204$4,025
Omeprazole105$2,341
Dicyclomine Hcl132$1,981
Hydrocortisone82$1,546
Sucralfate42$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$2,900$163,130145 claims
Aimmune Therapeutics, Inc.Zenpep$93$98,21143 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,493$25,32630 claims
Phathom Pharmaceuticals, Inc.Voquezna$326$10,95715 claims
Ferring Pharmaceuticals Inc.Clenpiq$176$6,14635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →